Long-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation

梅尔法兰 医学 多发性骨髓瘤 移植 自体干细胞移植 外科 全身照射 泌尿科 内科学 化疗 环磷酰胺
作者
Colton John Ladbury,George Somlo,Andy Dagis,Dongyun Yang,Saro H. Armenian,Joo Young Song,Firoozeh Sahebi,Ricardo Tomas Spielberger,Leslie L. Popplewell,Pablo Miguel Parker,Stephen J. Forman,DS Snyder,Amalia Rincon,An Liu,Paul Henry Frankel,Jeffrey Y.C. Wong
出处
期刊:Biology of Blood and Marrow Transplantation [Elsevier BV]
卷期号:28 (7): 367.e1-367.e9 被引量:6
标识
DOI:10.1016/j.jtct.2022.04.022
摘要

Total body irradiation in combination with melphalan for multiple myeloma (MM) has been shown to be prohibitively toxic. To ameliorate toxicity, total marrow irradiation (TMI) has been administered as the sole ablative modality during the second cycle of tandem autologous stem cell transplantation (TASCT) for MM patients on a phase I-II trial. Patients with MM in response or with stable disease and ≤18 months from diagnosis received melphalan 200 mg/m2 and autologous stem cell transplantation (ASCT) (cycle 1) and then, after recovery, TMI and another ASCT (cycle 2), followed by maintenance with an immunomodulatory drug (ImiD) and dexamethasone for up to 12 months. TMI doses were escalated from 1000 cGy to 1800 cGy in 200-cGy increments. Fifty-four patients were to receive TASCT between 2004 and 2011; 8 patients received single ASCT because of patient or physician preference. The median time between melphalan and TMI was 65 days (range, 47 to 125 days). Thirty patients (55.6%) underwent TASCT at the maximum tolerated dose of 1600 cGy. The complete response and very good partial response rates were 48.1% and 22.2%, respectively, following ASCT and maintenance. The median follow-up among survivors was 12.3 years (range, 9.2 to 15.5+ years). Progression-free survival (PFS) and overall survival at 10 years were 20.4% (95% confidence interval [CI], 10.9% to 31.9%) and 38.8% (95% CI, 25.9% to 51.5%), respectively. Secondary neoplasms included (1 each) acute myelogenous leukemia, papillary thyroid and prostate carcinoma, and melanoma, and there was 1 case of ductal carcinoma in situ and 4 cases of nonmelanoma skin cancers. TMI as part of TASCT was well tolerated, and TASCT was associated with a 20.4% PFS plateau. The inclusion of TMI as a conditioning regiment for MM before ASCT warrants further study in the context of modern induction and maintenance therapies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
康轩铭完成签到 ,获得积分10
刚刚
长青完成签到 ,获得积分10
1秒前
Yoopakho完成签到,获得积分10
1秒前
1秒前
Aoooo完成签到,获得积分10
1秒前
FashionBoy的应助被Sean采纳,获得10
2秒前
Dzinver完成签到,获得积分10
2秒前
2秒前
优雅的夏旋完成签到,获得积分10
2秒前
李健的应助被村口烫头祁师傅采纳,获得10
2秒前
任驰骋完成签到,获得积分10
3秒前
xiedi的应助被liu采纳,获得10
3秒前
3秒前
虚幻的靖儿完成签到 ,获得积分10
3秒前
suxinfeng完成签到,获得积分10
5秒前
搜集达人的应助被占博涛采纳,获得10
6秒前
哈47发布了新的文献求助10
6秒前
欢喜的楷瑞完成签到,获得积分10
6秒前
jackie完成签到,获得积分10
7秒前
无极微光的应助被叶95采纳,获得20
7秒前
CarryLJR的应助被Aoooo采纳,获得10
7秒前
shuyiWang发布了新的文献求助10
7秒前
百事可爱完成签到 ,获得积分10
8秒前
长青关注了科研通微信公众号
8秒前
今后的应助被xiaolong采纳,获得10
9秒前
奋斗的西装完成签到,获得积分10
10秒前
11秒前
清辉影的应助被XPR采纳,获得10
11秒前
小浅浅发布了新的文献求助10
11秒前
12秒前
科目三的应助被yuyuhong采纳,获得10
12秒前
麻瓜完成签到,获得积分10
12秒前
叫我老贾就好了完成签到,获得积分10
13秒前
丘比特的应助被科研通管家采纳,获得10
13秒前
田様的应助被科研通管家采纳,获得10
14秒前
英姑的应助被科研通管家采纳,获得10
14秒前
14秒前
慕青的应助被科研通管家采纳,获得10
14秒前
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181823
求助须知:如何正确求助?哪些是违规求助? 9571511
关于积分的说明 21818391
捐赠科研通 7778076
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479614